ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

9.55
0.01
(0.10%)
At close: 21 June 6:00AM
9.55
0.00
( 0.00% )
After Hours: 6:17AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
9.55
Bid
7.92
Offer
9.60
Volume
741,430
9.36 Day's Range 9.80
0.00 52 Week Range 0.00
Market Cap
Previous Close
9.54
Open
9.69
Last Trade
12
@
9.57
Last Trade Time
06:25:33
Financial Volume
US$ 7,107,146
VWAP
9.5857
Average Volume (3m)
-
Shares Outstanding
101,989,696
Dividend Yield
-
PE Ratio
-9.57
Earnings Per Share (EPS)
-1
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was US$9.54. Over the last year, Tango Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Tango Therapeutics currently has 101,989,696 shares in issue. The market capitalisation of Tango Therapeutics is US$974 million. Tango Therapeutics has a price to earnings ratio (PE ratio) of -9.57.

TNGX Latest News

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM, May 23, 2024 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq...

Tango Therapeutics Announces Discontinuation of TNG348 Program

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
1ADAdAlta Limited
AUD 0.026
(0.00%)
0
14DO1414 Degrees Limited
AUD 0.008
(0.00%)
0
14DN1414 Degrees Limited
AUD 0.00
(0.00%)
0
14D1414 Degrees Limited
AUD 0.066
(0.00%)
0
13S13 Seeds Limited
 0.00
(0.00%)
0
1ADAdAlta Limited
AUD 0.026
(0.00%)
0
14DO1414 Degrees Limited
AUD 0.008
(0.00%)
0
14DN1414 Degrees Limited
AUD 0.00
(0.00%)
0
14D1414 Degrees Limited
AUD 0.066
(0.00%)
0
13S13 Seeds Limited
 0.00
(0.00%)
0
TAHTabcorp Holdings Limited
AUD 1.31
(0.00%)
13.58M
SGRStar Entertainment Group Limited
AUD 2.94
(0.00%)
6.49M
NABNational Australia Bank Limited
AUD 37.01
(0.00%)
5.04M
MGRMirvac Group
AUD 2.41
(0.00%)
4.34M
AWCAlumina Limited
AUD 3.01
(0.00%)
3.73M

Your Recent History

Delayed Upgrade Clock